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Gliomas are solid brain tumors composed of tumor cells and recruited 
heterogenic stromal components. The study of the interactions between the 
perivascular niche and its surrounding cells is of great value in unraveling 
mechanisms of drug resistance in malignant gliomas.
In this study, we isolated the stromal diploid cell population from 
oligodendroglioma and a mixed population of tumor aneuploid and stromal 
diploid cells from astrocytoma specimens. The stromal cells expressed 
neural stem/progenitor and mesenchymal markers showing the same 
discordant phenotype that is typical for glioma cells. Moreover, some of 
the stromal cells expressed CD133. For the first time, we demonstrated 
that this type of stromal cells had the typical myofibroblastic phenotype 
as the α-SMA+ cells formed α-SMA fibers and exhibited the specific 
function to deposit extracellular matrix (ECM) proteins at least in vitro. 
Immunofluorescent analysis showed diffuse or focal α-SMA staining in the 
cytoplasm of the astrocytoma-derived, A172, T98G, and U251MG glioma 
cells. We could suggest that α-SMA may be one of the main molecules, 
bearing protective functions. Possible mechanisms and consequences of 









Gliomas represent a heterogeneous group of brain tumors 
characterized by a highly aggressive nature. Malignant glio-
blastoma exhibits a high self-renewal and proliferation ca-
pacity of glioma stem cells and perivascular niche cells. The 
study of the interactions between the perivascular niche and 
its surrounding cells is of great value in unraveling mecha-
nisms of drug resistance in malignant gliomas [1].
A neoplastic component of glioma consists of the trans-
formed cells of astrocytic or oligodendrocytic origin. Like 
all solid tumors in addition to the neoplastic component, 
glioma also contains a heterogeneous stroma which is 
comprised of prominent vessels and recruiting cells such 
as antigen-presented cells, reactive astrocytes, mesen-
chymal stem cells (MSC), and glioma-associated stromal 
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cells (GASC), termed also cancer-associated fibroblasts 
(CAFs) [2-4]. Neural stem or progenitor cells from the adult 
brain which are considered as the most putative cell of 
origin for glioma [5-8] may also be a part of the glioma 
tumor stroma. Some studies in xenograft models have 
shown that neural stem cells (NSC) can display extensive 
tropism toward the tumors [9-11]. In PDGF-induced gliomas 
stem or progenitor-like cells expressing neural markers 
can occupy large areas and even predominate in a tumor 
bulk [12-15]. Gene expression profiles of these cells resem-
ble ones of tumor cells. Moreover, the ability of the stro-
mal cells to acquire genetic alterations typical for gliomas 
has been shown in some experimental models [13]. Thus, 
identification of this type of stromal cells and obtaining 
its pure culture is rather difficult because it is poorly dis-
tinguishable from the tumor cells. The culture of neural 
stem/progenitor-like stromal cells has been obtained by 
using an artificial xenograft model [16]. The existence and 
proportion of this stromal cell component in gliomas are 
not clearly defined.
The role of the tumor microenvironment in cancer 
progression deserves significant attention. Cancer cells 
recruit and transform the stromal cells, which acquire my-
ofibroblastic phenotype determined by the expression of 
alpha-smooth muscle actin (α-SMA) [17-22]. Thus, Öhlund 
et al. [19] have identified a stromal cell subpopulation with 
elevated expression of α-SMA located immediately ad-
jacent to neoplastic cells in mouse and human pancreatic 
ductal adenocarcinoma tissue. Holm Nielsen [20] has found 
that the proportion of the α-SMA- positive myofibroblasts 
are upregulated in lung fibrosis and cancer. Vacz et al. 
[21] have demonstrated that the proportion of α-SMA(+)/
CK(+) cells is significantly higher in colorectal cancer 
samples compared to healthy or adenoma samples. The 
myofibroblast function is associated with extracellular ma-
trix (ECM) deposition in both normal physiological and 
pathological conditions [4,23]. Glia progenitor cells provide 
these functions in the CNS. During embryonic and postna-
tal development these purely differentiated cells exhibit a 
myofibroblastic phenotype and provide homing of neuron 
and glia precursors through the emerging brain areas [24-
26]. In the adult nervous system reactive glia demonstrates 
myofibroblastic features in response to injury [27]. These 
cells originate from the pool of progenitor cells dissem-
inated through the brain. Reactivated with inflammatory 
cues they take part in the formation of a glial scar in the 
central and peripheral nervous system of adults. The lev-
els of the same inflammatory cytokines (TGFβ1, IL6, etc.) 
were found to be elevated in neoplastic areas of the brain 
[28] that can result in the appearance of myofibroblasts 
accumulating in the tumor microenvironment. Recruiting 
CAFs, MSC and reactive astrocytes could be responsible 
for the production and modulation of ECM in gliomas. 
The ECM composition and stiffness are altered in malig-
nant gliomas and the correlation between these alterations 
and malignancy is discussed [29]. Whether neural stem/
progenitor-like stromal cells could demonstrate myofibro-
blastic features and contribute to ECM deposition during 
gliomagenesis remains unknown.
Glioma cells according to their probable origin should 
have a basic opportunity to exhibit the myofibroblastic phe-
notype and α-SMA shift. However, it has been shown that 
α-SMA expression is disrupted in transformed cells [30,31]. In 
oncogenic transformed fibroblasts these disruptions were me-
diated by repression of α-SMA promoter activity with serum 
response elements [32]. In a transformed rat cell line α-SMA 
was involved in the regulation of cell growth and motility 
and led to the suppression of the malignant phenotype of this 
cell line [33]. In tumor cells from primary and secondary glio-
blastomas α-SMA expression is absent in the cases when the 
loss of heterozygosity on chromosome 10q occurs [34]. In sec-
ondary glioblastomas, the repression of the α-SMA gene may 
be also associated with p53 mutations as the α-SMA gene 
has been shown to be a transcriptional target of this tumor 
suppressor protein [35]. It is not yet well explored if all glioma 
cells are unable to express α-SMA and to acquire myofibro-
blastic phenotype.
In this report, we isolated the stromal cell population 
from oligodendroglioma as well as the stromal and tu-
mor cells mixed population from anaplastic and fibrillar 
astrocytoma specimens. Both stromal and tumor glio-
ma-derived cells showed the same molecular profile indi-
cating that the cells belonged to the same lineage. We first 
demonstrated that the stromal cells expressing neural stem 
and progenitor markers had the typical myofibroblastic 
phenotype as they express α-SMA and exhibit their spe-
cific function to deposit ECM proteins at least in culture 
conditions. We also attempted to determine whether glio-
ma cells retain the expression of α-SMA.
2. Materials and methods
2.1 Tumor Specimens and Glioma-derived Cell 
Lines
Tumor samples were obtained from three patients un-
dergoing surgical treatment in the Polenov Neurosurgical 
Institute at Federal Almazov Medical Research Centre 
(St. Petersburg, Russia). These tumors were histologically 
characterized according to the WHO classification as ol-
igodendroglioma grade II (Olig II), fibrillar astrocytoma 
grade II (FAII) and polymorphic anaplastic astrocytoma 
grade III (AAIII). After surgical removal tumor samples 
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were kept in PBS at room temperature up to use and then 
they were washed, minced up to 1 mm3 pieces, enzymat-
ically treated, and passed through a syringe with a needle 
20G. The obtained suspension contained single cells and 
undissociated tissue pieces were plated on a culture plate. 
These cultures were further designated as “mix” cultures. 
Overnight unattached tumor pieces were transferred on a 
culture plate. Cell lines were obtained from these cultures 
by outgrowth of the cells from tumor pieces. When the 
cells reached confluence they were trypsinized, diluted 
and transferred on a plate. This standard procedure was 
repeated for all cell lines derived from primary cultures. 
The cell cultures were maintained in DMEM/F12 (Lonza, 
Belgium) supplemented with 10% fetal calf serum (Hy-
Clone Laboratories, Utah, USA), 2.5 mM L-glutamine, 
50 U/mL penicillin and 50 μg/mL streptomycin (Biolot, 
Russia) under standard conditions (37˚C, atmosphere of 
5% CO2 in air). Permanent human glioma cell lines A172, 
U251MG and T98G were obtained from the Vertebrate 
Cell Culture Collection at the Institute of Cytology RAS 
(St. Petersburg, Russia) and were maintained under the 
same culture conditions.
2.2 Magnetic Cell Separation of CD133+ Cells
The cells were harvested and resuspended in PBS con-
taining 0,5% BSA and 2 mM EDTA. Positive magnetic 
cell separation (MACS) was performed using the CD133 
MicroBead Kit (Miltenyi Biotec, Germany). The ratio of 
CD133+ cells was estimated by cell counting.
Immunocytochemical staining cells were grown on 
coverslips at high or low density for the indicated peri-
ods of time, then fixed with 4% formalin (Sigma, USA), 
permeabilized with 0.1% Triton X-100 or 0.5% Triton 
X-100 for nucleolin staining, and incubated with PBS 
containing 1% BSA (Sigma, USA) and 2% FCS for 30 
min to prevent unspecific binding of antibodies. Then, 
the samples were incubated with the following primary 
antibodies: mouse anti-α-SMA (1:300 dilution, Sigma), 
rabbit anti-GFAP (1:50, Sigma), mouse anti-CNPase (1:50, 
Chemicon), rabbit anti-nestin (1:50, Millipore), mouse 
anti-vimentin (1:150, Sigma), rabbit anti-collagen type I 
(1:40, Chemicon), mouse anti-fibronectin (1:200, Sigma), 
rabbit anti-CD133 (1:150, Abcam) or rabbit anti-nucleolin 
(1:100, Proteintech Europe) in 1% BSA overnight at 4°C. 
After washing with PBS samples were incubated with sec-
ondary antibodies Alexa-Fluor-488-conjugated goat anti-
mouse-IgG (1:400, Invitrogen) or Atto-550 conjugated 
goat anti-rabbit-IgG (1:300, Sigma), followed by staining 
with rhodamine-phalloidin (1:40, Invitrogen) and DAPI 
(2 μg/ml, Sigma). Then, the coverslips were mounted in 
Vectashield medium (Vector Laboratories). Samples were 
analyzed with the confocal fluorescence microscope Leica 
TCS SL (Leica Microsystems, Germany).
2.3 RNA Isolation and RT-PCR
Total RNA was isolated from cells with the GenJET 
RNA purification kit (Thermo Scientific, Lithuania) 
according to the manufacturer’s instructions. RNA con-
centration was determined with an ND1000 spectropho-
tometer (NanoDrop, USA). RNA solutions were stored at 
-80°C. Sample volumes from 0.5 to 11 μL of total RNA 
solution (depending on RNA concentration) were used in 
a volume of 20 μL for each reaction of the reverse tran-
scription. The reaction was performed with a RevertAid 
reverse transcriptase kit (Thermo Scientific, Lithuania) 
according to the manufacturer’s instructions using random 
hexamer primers. cDNA was stored at -20°C. PCR was 
performed at a volume of 25 μL with DreamTaq DNA 
polymerase (Thermo Scientific, Lithuania) according to 
the manufacturer’s instructions. DNA was amplified for 
35 cycles. PCR products were analyzed by electrophoresis 
in 2% agarose gel. Gel image acquisitions were made with 
the ChemiDoc system (Bio-Rad, USA). Primers were 
designed using primer-BLAST resources of the National 
Center for Biotechnology Information (NCBI) and an IDT 
OligoAnalyzer (http://eu.idtdna.com/calc/analyzer). Prim-
ers for vimentin gene identification corresponded to the 
reported sequences (Velpula et al., 2011). The following 
primers sequences were used:
Vimentin, 5′-GAACGCCAGATGCGTGAAATG-3′ (forward),
 5′ CCAGAGGGAGTGAATCCAGATTA-3′ (reverse); 





 5′ CAGTGACGTTCACTACGGCT-3′ (reverse); 
CD133, 5′-GGTGCTGTTCATGTTCTCCA-3′ (forward),
 5′ ACCGACTGAGACCCAACATC-3′ (reverse);
β-actin, 5′-TTCCTGGGCATGGAGTCCT-3′ (forward),
 5′-AGGAGGAGCAATGATCTTGATC-3′ (reverse).
2.4 Fluorescence-activated Cell Sorting Analysis
The cells were grown to 80-90% confluence, trypsin-
ized with 0.25% Trypsin-EDTA (Gibco), washed with 
PBS, centrifuged at 1,000 rpm for 5 min, and the pellet 
was resuspended at a concentration of 1 x 106/mL. Glioma 
cells were stained with fluorochrome-conjugated antibod-
ies for at least 30 minutes at 4 °C and then the samples 
were diluted by FACS buffer (PBS with 1% BSA and 
0.05% sodium azide). The analyses were made on a flow 
DOI: https://doi.org/10.30564/jor.v3i2.3566
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cytometer CyFlowSpace (Partec, Germany) and ≥10,000 
events were collected in each analysis with forward scatter 
and side scatter. Data were analyzed by FloMax 2.82 soft-
ware (Partec, Germany). The following antibodies were 
employed: CD44-FITC, CD73-PE, CD105-PE, CD90-
FITC, CD29-PE, CD13-PE, CD9-FITC, CD130-FITC, 
CD146-PE, CD10-FITC, CD11b-PE, CD45-FITC, and 
HLA-DR-PE (Beckman Coulter, BD Pharmigen, Chem-
icon, Caltag Laboratories, Becton Dickinson, and eBio-
science). Mouse IgG-FITC and IgG-PE isotype controls 
(DAKO) were used for assessing the background staining 
of cells.
For DNA content analysis, cells were suspended in 
300 µl PBS containing 200 µg/ml of saponin (Fluka, NY, 
USA), 250 µg/ml RNase A (Sigma, St. Louis, MO, USA, 
number R4642), and 50 µg/ml PI, incubated for 60 min 
at room temperature and subjected to FACS analysis. At 
least 10,000 cells were measured per sample. Normal hu-
man lymphocytes were used as internal diploid control. 
Samples were analyzed by flow cytometer CytoFLEX. 
Histograms were prepared using CytExpert program ver-
sion 1.2 (Beckman Coulter, Brea, CA, USA). DNA index 
(DI) was determined as the ratio of the mean DNA content 
of the glioma-derived cells to the mean DNA content of 
the control diploid cells.
2.5 Western Blotting
Total protein was isolated from monolayer cells at 72 
h after plating. Briefly, the cells were washed with PBS 
and collected in RIPA lysis buffer containing a protease 
inhibitor cocktail (Sigma). The lysates were clarified by 
centrifugation at 14,000×g at 4°C for 15 min. Protein con-
centrations were determined by the Pierce BCA protein 
assay kit (Thermo Fisher Scientific) with BSA as a stand-
ard, and an equal mass of proteins from the cell samples 
were resolved on a 10% SDS polyacrylamide gel. In the 
case of analysis of collagen type I and α-SMA in glioma 
cell lines 25 μg of protein per lane was applied, in all 
other cases - 10 μg of protein per lane. After that, the pro-
teins were electrotransferred onto a nitrocellulose mem-
brane (Biorad). After blocking in PBS buffer with 0.05% 
Tween-20 (PBS-T) containing 5% nonfat dry milk at 
room temperature for 1 hr, blots were incubated overnight 
at 4°C with monoclonal anti-α-SMA antibodies (1:1000, 
Sigma, A5228), or polyclonal anti-β-tubulin antibodies 
(1:1000, Abcam, AB6046) or polyclonal anti-collagen 
type I antibodies (1:200, Chemicon, AB745) in blocking 
buffer. After three washes with PBS-T, the membranes 
were incubated for 1 hr at room temperature with rabbit 
peroxidase-labeled anti-mouse-IgG secondary antibodies 
(1:20000, Thermo Fisher Scientific, #31431) or with goat 
peroxidase-labeled anti-rabbit-IgG secondary antibodies 
(1:20000, Sigma, A0545) in blocking buffer. Membranes 
were washed three times with PBS-T and then were in-
cubated in the chemiluminescent substrate (SuperSignal 
West Femto Maximum Sensitivity Substrate, Thermo 
Fisher Scientific, #34095) and visualized on Fusion FX 
imager (Vilber Lourmat). Densitometric analysis of the 
bands was performed by employing Fusion-FX software 
(Vilber Lourmat).
3. Results
The stromal cells growing from tumor pieces 
together with tumor cells are not MSC, microglia/
macrophages, or endothelial/subendothelial cells
The cells were isolated from glioma specimens by dif-
ferent approaches and compared cellular morphology and 
phenotype. The glioma-derived cultures obtained from the 
fraction of tumor pieces by cell sprouting presented mor-
phologically homogeneous cell populations. At early pas-
sages, FAII- and AAIII -derived cells had polygonal epi-
thelial-like shapes whereas ones derived from OligII had 
elongated fibroblast-like morphology (Figure 1). Further, 
the cells were enlarged and acquired a flattened shape.
To characterize the cell cultures and estimate their 
homogeneity we used flow cytometry for cell surface 
markers which are generally expressed on glioma cells 
and cells relating to the tumor stroma such as microglia, 
macrophages, pericytes, endothelial, smooth muscle, and 
Figure 1. Phase-contrast images of oligodendroglioma grade II (OligII), fibrillar astrocytoma grade II (FAII), anaplas-
tic astrocytoma grade III (AAIII)-derived cells grown out from tumor micro fragments, and cells representing a mixed 
fraction of single cells and tumor pieces (FAII mix).
DOI: https://doi.org/10.30564/jor.v3i2.3566
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mesenchymal stem cells (Table 1).
Table 1. Phenotypic analysis of FAII, FAII mix, AAIII, 
AAIII mix, and A172 cells by flow cytometry.
FAII FAII mix AAIII AAIII mix A172
CD44 99,6 99,8 97,5 94 98,4
CD73 99,9 99,7 99 75 4,8
CD105 99,7 99,7 95,5 71 39,8
CD90 4,4 61 3,6 1,2 21
CD29 99,8 99,9 93 93 98
CD13 99,8 94,6 99,5 96 13
CD9 100 99,8 71 87
CD146 5,8 23 2,9 2,8 97
CD130 1,1 0,4 1,6 1 7,3
CD10 0,2 0,1 3,2 0,7
CD11b 0,2 1,6 20
CD45 0,2 0,2
HLA-DR 3,5 25,5
Cells were immunostained with antibodies against mes-
enchymal markers (CD44, CD73, CD105, CD90, CD29, 
and CD13), endothelial, subendothelial and mesenchymal 
marker CD146, microglia/macrophages markers (CD11b, 
CD45 and HLA-DR), CD9, CD130, and CD10.
FAII- and AAIII -derived cells showed a similar surface 
molecular pattern: high level of mesenchymal markers 
CD44, CD73, CD105, CD29, CD13, but low CD90; low 
level of CD146, the laminin receptor, which is typical for 
pericytes, endothelial, smooth muscle and also mesenchy-
mal stem cells; negligible levels of microglia/macrophages 
markers CD11b, CD45. For comparison, we analyzed the 
A172 permanent cell line and revealed a modified pattern 
of mesenchymal markers, e.g. low percentage of CD73+ 
and CD13+ cells that may be the result of the long-term 
culturing and clonal cell selection in permanent cell lines. 
This assumption is consistent with the detection of high 
expression of CD146 marker in A172 permanent cell line 
since this molecule is associated with clonal properties [36].
Flow cytometry analysis of FAII mix and AAIII mix 
cultures obtained from the mixed fraction of single cells 
and tumor pieces revealed double peaks on graphs for a 
number of surface markers whereas only one peak for the 
corresponding markers was revealed in FAII and AAIII 
cultures obtained from tumor pieces only (Figure 2A, 
B). Thus, FAII mix culture contained 61% CD90+ cells, 
most likely MSCs, though almost no CD90 expressing 
cells were present in FAII culture (Figure 2A). Appar-
ently, these stromal cells could be detected visually as 
elongated cells grouped together in FAII mix culture (Fig-
ure 1). HLA-DR positive cells presumably representing 
microglia/macrophages dominated in AAIII mix culture 
compared to AAIII culture (25% vs 3.5%) (Figure 2B). 
Therefore, cells grown intensively from the tumor pieces 
arise to a morphologically homogeneous cell population 
depleted for MSC and microglia/macrophages that appear 
to be a significant part of the cell culture obtained from 
completely dissociated tumor tissue.
In spite of morphological and surface marker homo-
geneity of FAII and AAIII cell cultures, the analysis of 
DNA content by flow cytometry revealed two distinct cell 
populations: normal stromal diploid and tumor aneuploid 
(Figure 2C). Aneuploid cell populations in both astrocyto-
ma-derived cell lines were nearly tetraploid (DI was 1,86 
(P2) and 1,85 (P6) for FAII, and 1,88 (P5) and 1,89 (P15) 
for AAIII), the second histogram peak in the PI channel 
coincides with overlapping aneuploid (G1/G0) tumor cell 
population and the diploid 4N (G2/M) stromal cell frac-
tion. Interestingly, the proportion of aneuploid and diploid 
cells remained nearly constant over the passages and was 
higher in AAIII than FAII cell culture. It may reflect the 
mutual influence of the tumor and stromal cells and the 
establishment of a stabilized ratio of the cell types in cul-
ture. According to the DNA assay, OligII cells were all 
diploid (Figure 2C) pointing to the absence of neoplastic 
component. It is consistent with reports where it has been 
demonstrated that oligodendroglioma tumor cells are not 
viable in culture under adherent conditions [16,37].
The stromal cells are α-SMA+ and responsible for 
the deposition of collagen type I and fibronectin. Al-
pha-smooth muscle actin (α-SMA) is regarded to be one 
of the most significant markers of stromal cells in gliomas 
[2]. Immunostaining with monoclonal antibody to α-SMA 
confirmed the presence of a stromal component in as-
trocytoma-derived cell cultures FAII and AAIII (Figure 
3A). Numerous cells with well-organized α-SMA-fila-
ments were seen (α-SMA+ cells). Of note, cells without 
α-SMA-filaments had a diffuse cytoplasmic α-SMA 
staining. OligII-derived cell culture was a total α-SMA+ 
stromal cell population according to immunofluorescence 
(Figure 3A). Western blot analysis revealed the highest 
level of α-SMA in OligII cells (Figure 3B). Interesting-
ly, FAII mix culture in which MSCs were about 60% of 
the total cell population showed α-SMA level lower than 
FAII cells (Figure 3B) in which MSC were only about 4% 
of the total cell population according to flow cytometry 
(Figure 1C). This fact suggests that there are neural stem/
progenitor-like stromal cells in glioma that produce more 
α-SMA than MSCs.
In order to estimate the specific fibrotic potential of 
α-SMA+ cells, the intracellular synthesis of collagen type 
I and fibronectin and their deposition in ECM were com-
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Figure 2. Phenotypic characterization of cells derived from glioma specimens.(A) Flow cytometry assay of CD90 and 
CD146 expression in FAII mix and in FAII cultures. (B) Flow cytometry assay of CD73 and HLA-DR expression in 
AAIII mix and AAIII cultures. (C) DNA assays of cells derived from glioma specimens. Flow cytometry histograms 
showing the DNA content in FAII, AAIII, and OligII cells. Stromal cells and lymphocytes were DNA diploid (DI=1). 
Tumor cells were aneuploid: FAII (DI=1,86 (2P) and 1,85 (6P)) and AAIII (DI=1,88 (5P) and 1,89 (15P)).
According to immunofluorescence at the 15-th day of 
culturing the deposition of collagen type I and fibronectin 
was more abundant in OligII culture (Figure 3D). FAII 
and AAIII cultures showed resembling the pattern of pro-
tein deposition with an increased level in FAII culture. 
These results suggest that there is a positive correlation 
between the amount of α-SMA+ cells and collagen type 
I and fibronectin deposition. These results also show that 
the ability of glioma-derived stromal cells to produce 
ECM may have a tendency to decline with malignancy 
development.
Glioma cells usually do not express α-SMA and show 
reduced deposition of collagen type I and fibronectin
As NSC from the subventricular zone and glia progen-
itors from brain parenchyma are believed to be the cell 
DOI: https://doi.org/10.30564/jor.v3i2.3566
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Figure 3. α-SMA+ stromal cell component of primary cultures and permanent glioma cell lines, their fibrotic potential. 
(A) Immunocytochemical staining of α-SMA in OligII, FAII, and AAIII cultures and glioma cell lines. (B) Western blot 
analysis of α-SMA in OligII, FAII, AAIII, FAII mix cells and glioma cell lines. (C) Western blot analysis of α-SMA and 
collagen type I in AAIII culture and glioma cell lines. (D) Immunocytochemical staining of α-SMA and collagen type I 
(upper horizontal line) intracellularly after 3 days in culture, and collagen type I (central horizontal line) and fibronectin 
(bottom horizontal line) extracellularly after 15 days in culture. (E) Double immunocytochemical staining of α-SMA 
and nucleolin in AAIII and A172 cells. Localization of α-SMA in nucleoli of A172 and no staining in the AAIII cells.
DOI: https://doi.org/10.30564/jor.v3i2.3566
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of origin for glioma [5-8] and can express α-SMA [24-26], 
we attempted to determine whether glioma cells express 
α-SMA. Immunostaining of α-SMA in three permanent 
glioma lines A172, T98G, and U251MG revealed that the 
A172 cell line contained a few α-SMA+ cells with their 
numbers increasing over the time spent in culture (Figure 
3A). A172 cells without α-SMA fibers showed negligible 
α-SMA staining in the cytoplasm and distinct spotted sig-
nal in the nucleus. The presence of α-SMA+ cells pointed 
to the basic opportunity of glioma cells to synthesize 
α-SMA and became additional proof for the neural stem/
progenitor cell nature of glioma cells. Although T98G and 
U251MG lines did not have cells containing α-SMA-fila-
ments they exhibited a homogeneous strong α-SMA stain-
ing in the cytoplasm as well as a spotted α-SMA staining 
in the nucleus (Figure 3A).
Western blot analysis revealed a very weak α-SMA 
band in A172 cells that apparently correspond to α-SMA+ 
cells, and did not reveal α-SMA full-length protein (43 
kDa) in T98G and U251MG lines in which the α-SMA+ 
cells were absent (Figure 3C). Taking into account that 
T98G and U251MG cells have mutations and A172 cells 
have a deletion in tumor suppressor PTEN gene [38] which 
is located side by side with Acta2 gene encoding α-SMA, 
we speculate that α-SMA protein could also be altered so 
that F-actin assembly was disrupted in permanent glio-
ma lines. We speculate further that this altered protein of 
α-SMA might not be revealed in denatured form by elec-
trophoresis but might be stained in native form by immu-
nocytochemistry.
In order to estimate the fibrotic potential of tumor cells, 
the intracellular synthesis of collagen type I and fibronec-
tin and their deposition in ECM were compared between 
AAIII cells and A172, T98G, and U251MG cell lines by 
Western blotting and immunofluorescence (Figure 3C, 
3D). Western blot analysis revealed a more reduced intra-
cellular synthesis of collagen type I in the permanent cell 
lines compared to AAIII cells (Figure 3C). The deposition 
of collagen type I and fibronectin by A172 cells at the 15-
th day of culturing was also significantly reduced com-
pared with glioma-derived cells (Figure 3D).
Because a strong α-SMA spotted positivity was ob-
served in the nucleolar area in all permanent cell lines, we 
performed co-immunostaining of α-SMA with nucleolin 
as a marker for nucleoli (Figure 3E). The results clearly 
showed that nuclear α-SMA was localized exclusively 
in the nucleoli. Of note, the α-SMA+ A172 cells also ex-
hibited distinct nucleolar α-SMA localization. Nucleolar 
localization of α-SMA was also detectable in glioma-de-
rived cells, although the fluorescent intensity was much 
lower, sometimes barely visible. These results suggest that 
α-SMA-altered forms could perform cellular functions 
differently from wild-type α-SMA. Nucleolar localization 
of α-SMA could be associated with clonal properties of 
the long-term culturing permanent cell lines and, there-
fore, with a more proliferative phenotype. Similarly, nu-
cleolar localization of many proteins occurs in highly pro-
liferating cells. Furthermore, the presence of β-actin and 
non-muscle myosin 1 was shown in the nucleoli of HeLa 
cells where they were involved in the regulation of RNA 
synthesis [39].
The stromal glioma-derived cells express neural 
stem/progenitor, glial and mesenchymal markers
As α-SMA+ stromal cells growing from pieces of tu-
mor tissues together with glioma cells did not have a mes-
enchymal stem or endothelial/subendothelial cell nature 
according to FACS analysis (Figure 1B), we assumed their 
neural stem/progenitor cell origin. Immunocytochemical 
staining of GFAP and CNPase, astrocyte and oligodendro-
cyte markers respectively, revealed co-expression of these 
glia proteins in all cells of glioma-derived cell cultures 
pointing to their glia precursor cell origin (Figure 4A). 
CNPase, the enzyme related to multiple cellular functions, 
displayed a distinct fluorescent signal and was typical 
for glial cells mitochondrial localization. Well-organized 
GFAP intermediate filaments were mostly seen in OligII 
cells. The majority of the astrocytoma cells showed dif-
fuse staining of GFAP. RT-PCR amplification revealed 
expression of glia progenitor’s markers GFAP, NG2, as 
well as mesenchymal markers vimentin and CD44 in the 
glioma-derived cell cultures (Figure 4B).
To be sure that α-SMA+ stromal cells indeed produce 
the neural stem/progenitor cell proteins, double immunos-
taining of α-SMA together with proteins related with low 
or either high malignant phenotype was performed. GFAP, 
the astrocyte marker, was stained in all α-SMA+ cells of 
all cultures, and even a strong staining signal was revealed 
in few cells (data not shown). Co-staining with nestin, the 
protein associated with high malignancy, revealed ambig-
uous results (Figure 4C). On the one hand, OligII α-SMA+ 
cells co-expressed nestin highly. The AAIII and FAII 
astrocytoma cells showed an unaltered or decreased level 
of nestin staining in α-SMA+ cells. Cells without α-SMA 
synthesis found only in AAIII culture showed a high level 
of nestin. This tumor cell population may potentially have 
more invasive features.
Furthermore, RT-PCR analysis revealed that all glio-
ma-derived cell cultures expressed transcripts encoding 
CD133 which are specific for cancer and neural stem cells 
(Figure 4B). We performed magnetic cell sorting of AAIII 
and OligII cultures and revealed that AAIII-CD133- and 
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OligII-CD133-enriched fraction reached no less than 10% 
of the total cell population. Following immunofluores-
cence showed that the cells displayed typical membranous 
fluorescent signal as well as distinct atypical nuclear lo-
calization of CD133. Unexpectedly, the AAIII-CD133-en-
riched fraction turned out similar to AAIII culture in terms 
of the presence of α-SMA+ cells. Double immunostaining 
of α-SMA and CD133 showed co-expression of these pro-
teins (Figure 4D). However, α-SMA+ cells showed often 
more weak or negligible dotted signal of CD133 than cells 
with diffuse staining of α-SMA. Thus, CD133 expression 
seems to be inhibited in the α-SMA+ astrocytoma-derived 
cells. However, CD133+ OligII stromal cells that are 
total α-SMA+ cell population according to previous re-
sults (Figure 3A) showed distinct dotted signal in nuclei. 
Despite these differences, taken together, these results 
demonstrate that the stromal cells showed phenotypic 
mimicry with tumor cells.
4. Discussion and Conclusions
Figure 4. Expression of neural stem/progenitor, glial and mesenchymal markers in glioma-derived cells. (A) Co-expres-
sion of GFAP and CNPase in OligII, FAII, and AAIII cells. (B) RT-PCR assay of expression of mesenchymal, glial pro-
genitor’s markers and CD133 in the glioma-derived cultures. (C) Co-expression of α-SMA and nestin in glioma-derived 
cells. α-SMA expression is absent in some the nestin-positive AAIII cells. (D) Expression of CD133 in OligII stromal 
cells and in α-SMA+ cells from CD133-enriched AAIII culture.
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In this study, we isolated a mixed population of tumor 
and stromal cells which rapidly grew out from the tumor 
micro fragments. They shared a similar phenotype and 
were undistinguishable morphologically at the zero pas-
sage. As the tumor cells, the stromal cells showed a high 
expression of mesenchymal markers vimentin and CD44 
as well as nestin, the protein associated with neuroepi-
thelial development. Additional expression of both GFAP 
and CNPase, astrocytic and oligodendrocytic markers 
respectively, and other glia progenitor protein such as 
NG2, demonstrated the same discordant phenotype for the 
stromal cells as glioma cells have [40]. Moreover, the stro-
mal cells expressed CD133, the protein associated with 
stemness which is not found in MSC and GASC [41-43]. All 
these facts indicate that this type of stromal cells could 
originate from the same lineage as the tumor cells.
NSCs from the subventricular zone and glia pro-
genitors from subcortical white matter are discussed as 
the most likely cell of origin for glioma [5-8]. After an 
expansion of transformed cells, “normal” neural stem 
or progenitor cells may be induced to proliferation by 
glioma cells and migrate together with them to form tu-
mor mass. The presence of NSCs in the tumor bulk has 
been revealed in PDGF-induced gliomas, along with that 
tropism of “normal” NSCs and glia progenitors from the 
adult brain to glioma was demonstrated in orthotopic 
xenograft models [12-15]. The stromal cells may constitute 
a considerable part of the tumor mass. Thus, it has been 
shown that 90% of glioma specimens are composed of the 
cells that expressed A2B5, the marker of glia progenitors 
from the adult forebrain [6,7]. At the same time, mimicry of 
many glioma-associated markers can make them poorly 
distinguishable by immunohistochemical analysis. We 
first showed that the stromal cells with neural stem/pro-
genitor-like cell phenotype can be easily isolated from 
tumor specimens together with tumor cells and expanded 
in culture. Interestingly, the ratio of tumor and stromal 
cells maintained stable through many passages with the 
predominance of stromal cells. This could result from the 
significant growth potential of both cell types maintained 
by crosstalk between them.
Myofibroblastic phenotype accompanied by α-SMA 
expression is the main sign of the stromal cells in glio-
ma-derived cultures. This feature of the stromal cells with 
neural stem/progenitor-like cell phenotype is not contra-
dictory considering that there are glia progenitor cells in 
the embryonic and neonatal brain that express α-SMA and 
exhibit myofibroblastic features [24-26]. Other cells of neural 
origin capable to produce α-SMA are reactive astrocytes 
from the adult brain that can gain myofibroblastic pheno-
type induced by inflammatory cues in response to injury [27]. 
A high concentration of the same inflammatory cytokines 
is detected in glioma bulk and peritumoral space and 
may stimulate the formation of cells with myofibroblastic 
phenotype. However, α-SMA immunoreactivity is almost 
exclusively revealed in the blood vessels on immunohisto-
chemical sections of glioma [16]. It means that our finding 
is a cultural phenomenon and in vivo, the stromal cells 
with neural stem/progenitor-like cell phenotype either do 
not switch on the α-SMA expression or express this pro-
tein on a very low level. But we assume that even with the 
low level of α-SMA expression the stromal cells in glioma 
may maintain deposition of ECM and contribute to fibrot-
ic processes in glioma.
The expression of α-SMA is thought to be absent in gli-
oma cells, but taking into consideration a possible origin 
of glioma cells from NSC or glia progenitors we studied 
whether glioma cells could express this protein. We found 
that tumor cells showed diffuse α-SMA immunostaining in 
the cytoplasm from very weak in A172 cells and moderate 
in astrocytoma-derived tumor cells up to strong in T98G 
cells. Moreover, a few of the A172 cells demonstrated 
the ability to form α-SMA filaments. U251MG cells had 
strong focal α-SMA staining. In addition, distinct spotted 
staining in the nucleoli was seen in permanent cell lines. 
The resembling variable diffuse or focal cytoplasmic 
staining of α-SMA has been revealed in neoplastic cells 
of gastrointestinal stromal tumors [43,44]. HeLa cells show a 
characteristic spot-like pattern of β-actin and non-muscle 
myosin 1 in the nucleoli where the actin-myosin complex 
has been shown to regulate mRNA synthesis [26]. Never-
theless, western blot analysis did not reveal full-length 
α-SMA (43kD) in T98g and U251MG cell lines in which 
the α-SMA+ cells are absent. In T98g and U251MG cells, 
α-SMA could be represented by altered monomeric forms 
which are not recognized by antibodies against wild-type 
α-SMA during western blot analysis. This assumption is 
consistent with the fact that the ACTA2 gene encoding 
α-SMA is located on a long arm of chromosome 10 in one 
of the most mutagen regions typical for gliomas [34,45,46]. 
Anaplastic astrocytomas and glioblastomas progressing 
from low-grade astrocytomas often show a reduced num-
ber of chromosome segments on 10q [47]. It is also note-
worthy that the gene of tumor suppressor, PTEN, which is 
the most frequently lost in gliomas [46,48], is adjacent to the 
ACTA2 gene [45]. Like PTEN, the ACTA2 gene must have 
massive mutagenic pressure. In particular, all three perma-
nent glioma cell lines used in the current work have ab-
normal PTEN alleles [38]. Mutations or deletions of α-SMA 
gene in gliomas could disrupt the filament formation in 
the same way as it occurs in smooth muscle cells or as it 
has been demonstrated for β-actin [50-52].
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It is remarkable that the p53 tumor suppressor has the 
ability to directly activate the transcription of the α-SMA 
gene [35]. Thus, the mutations in the p53 gene can affect 
α-SMA expression and they are actually the genetic hall-
marks of secondary glioblastomas. At the same time, the 
entire loss of chromosome 10 containing the ACTA2 gene 
is typical for primary glioblastomas [34,53-54]. Taken together 
these facts may imply that the loss or decrease of α-SMA 
expression with disruption of fiber assembly are factually 
obligate for glioblastomas and seems to play a critical role 
in malignant transformation. Indeed, α-SMA inhibits both 
migration and proliferation of normal and transformed 
cells due to the forming of focal adhesions and by pre-
venting the activation of small GTPase Rac1 [55-56]. At the 
same time, the deposition of ECM which is an attribute of 
α-SMA+ cells in many tissues can also inhibit migration 
[57-58]. Loss of α-SMA studied in ACTA2 mutant smooth 
muscle cells induced their proliferation through FAK and 
Rac1 activation, translocation of p53 from the nucleus to 
the cytoplasm, and increased expression and ligand-inde-
pendent activation of PDGF receptor β [59]. On the other 
hand, in the case of disruption of microfilament bundle 
assembly due to missense ACTA2 mutations, an increased 
pool of monomeric actin leads to additional proliferative 
response through binding G-actin with MRTF-A, a mem-
ber of the myocardin family of transcriptional coactiva-
tors. Thereby it allows SRF to bind to growth responsive 
genes [52,60]. The proliferative pathways induced by mon-
omeric α-SMA might be the same in malignant cancer 
cells. In addition, monomeric α-SMA apparently stimu-
lates motility: the presence of α-SMA has been shown in 
the leading edge of astroglia lamellipodia [25]. Therefore, 
we hypothesize that the existence of monomeric α-SMA 
in the tumor cells of anaplastic astrocytomas and benign 
gliomas could be a significant pathogenetic and prognos-
tic sign.
There is a possibility that similar disruptions of α-SMA 
expression occur in the stromal component of gliomas. 
Fomchenko et al. [13] have demonstrated that genetic ab-
errations typical for glioma cells may be acquired by nor-
mal cells recruited into the tumor. Disruptions of α-SMA 
expression imply that myofibroblastic functions including 
ECM deposition can be impaired. ECM in turn may re-
strain tumor spread and so the impairment of its deposi-
tion facilitates tumor growth. Growing disturbances of 
α-SMA expression in stromal cells with increasing malig-
nancy grade would induce their proliferation and, in fact, 
remove the main differences between stromal cells with 
neural stem /progenitor-like phenotype and glioma cells.
In this report, we have raised the question about a pos-
sible role of α-SMA breakdown in gliomagenesis. Taken 
together our findings and published literature data suggest 
that α-SMA may be one of the main molecule bearing 
protective functions, and its loss, as well as microfilament 
assembly disruptions in tumor and stromal cells, seems to 
be fatal in the way of glioma progression.
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